Affordable Access

Comparing intramuscular progesterone, vaginal progesterone and 17 -hydroxyprogestrone caproate in IVF and ICSI cycle.

Authors
  • Moini, Ashraf1
  • Zafarani, Fatemeh2
  • Eslami, Bita3
  • Sadeghi, Maria4
  • Kamyabi, Zahra4
  • Jahangiri, Nadia4
  • 1 Department of Endocrinology and Female Infertility, Royan Institute of Reproductive Biomedicine, ACECR, Tehran, Iran. ; Department of Obstetrics and Gynecology, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran. , (Iran)
  • 2 Department of Endocrinology and Female Infertility, Royan Institute of Reproductive Biomedicine, ACECR, Tehran, Iran. ; Department of Reproductive Imaging, Royan Institute, ACECR, Tehran, Iran. , (Iran)
  • 3 Department of Obstetrics and Gynecology, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran. , (Iran)
  • 4 Department of Endocrinology and Female Infertility, Royan Institute of Reproductive Biomedicine, ACECR, Tehran, Iran. , (Iran)
Type
Published Article
Journal
Iranian journal of reproductive medicine
Publication Date
Jan 01, 2011
Volume
9
Issue
2
Pages
119–124
Identifiers
PMID: 25587258
Source
Medline
Keywords
License
Unknown

Abstract

The effects of three types of progesterone were similar on pregnancies rate. We suggest the use of intravaginal progesterone during the luteal phase in patients undergoing an IVF-ET program because of the low numbers of abortions, and high ongoing pregnancy rates.

Report this publication

Statistics

Seen <100 times